caa a22 4500 445335610 CHVBK 20180317142754.0 cr unu---uuuuu 170323e20111001xx s 000 0 eng 10.1245/s10434-011-1640-4 doi (NATIONALLICENCE)springer-10.1245/s10434-011-1640-4 Contrasting Prognostic Implications of Platelet-Derived Growth Factor Receptor-β and Vascular Endothelial Growth Factor Receptor-2 in Patients with Angiosarcoma [Elektronische Daten] [Kan Yonemori, Koji Tsuta, Masashi Ando, Akihiro Hirakawa, Yutaka Hatanaka, Yoshihiro Matsuno, Hirokazu Chuman, Naoya Yamazaki, Yasuhiro Fujiwara, Tadashi Hasegawa] Background: Angiosarcoma is an extremely rare tumor among sarcomas and comprises a heterogeneous group of high-grade vascular malignancies. Our study aimed to examine the correlations between 6 immunohistochemical biomarkers—stem cell factor receptor (KIT), platelet-derived growth factor receptor (PDGFR)-α, PDGFR-β, vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, and VEGFR-3—and overall survival (OS) in patients with angiosarcomas. Methods: Immunohistochemical analyses for the 6 biomarkers were performed by using tumor specimens obtained from 34 patients with angiosarcomas. Correlations between biomarkers were examined by Fisher's exact test. For each biomarker, the correlation between the immunohistochemical score and OS was examined by the log-rank test and Cox regression analysis. Results: The percentages of angiosarcoma patients with positive expressions (immunohistochemical score>0) of KIT, PDGFR-α, PDGFR-β, VEGFR-1, VEGFR-2, and VEGFR-3 were 14.7%, 11.8%, 88.2%, 61.8%, 94.1%, and 100.0%, respectively. No statistically significant correlations between any 2 biomarkers were observed. Cox regression analysis demonstrated a significant positive correlation between short OS and the immunohistochemical score for PDGFR-β and between long OS and the immunohistochemical score for VEGFR-2. Conclusion: Increased expression of PDGFR-β may be a statistically significant prognostic factor for poor OS, while increased expression of VEGFR-2 may be a favorable prognostic factor for patients with angiosarcoma. Society of Surgical Oncology, 2011 Yonemori Kan Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan aut Tsuta Koji Department of Clinical Laboratory, National Cancer Center Hospital, Tokyo, Japan aut Ando Masashi Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan aut Hirakawa Akihiro Department of Management Science, Graduate School of Engineering, Tokyo University of Science, Tokyo, Japan aut Hatanaka Yutaka Department of Surgical Pathology, Hokkaido University Hospital, Sapporo, Hokkaido, Japan aut Matsuno Yoshihiro Department of Surgical Pathology, Hokkaido University Hospital, Sapporo, Hokkaido, Japan aut Chuman Hirokazu Department of Orthopedic Surgery, National Cancer Center Hospital, Tokyo, Japan aut Yamazaki Naoya Department of Dermatology, National Cancer Center Hospital, Tokyo, Japan aut Fujiwara Yasuhiro Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan aut Hasegawa Tadashi Department of Surgical Pathology, Sapporo Medical University School of Medicine, Sapporo, Hokkaido, Japan aut Annals of Surgical Oncology Springer-Verlag 18/10(2011-10-01), 2841-2850 1068-9265 18:10<2841 2011 18 10434 https://doi.org/10.1245/s10434-011-1640-4 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1245/s10434-011-1640-4 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Yonemori Kan Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan aut NATIONALLICENCE 700 1- Tsuta Koji Department of Clinical Laboratory, National Cancer Center Hospital, Tokyo, Japan aut NATIONALLICENCE 700 1- Ando Masashi Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan aut NATIONALLICENCE 700 1- Hirakawa Akihiro Department of Management Science, Graduate School of Engineering, Tokyo University of Science, Tokyo, Japan aut NATIONALLICENCE 700 1- Hatanaka Yutaka Department of Surgical Pathology, Hokkaido University Hospital, Sapporo, Hokkaido, Japan aut NATIONALLICENCE 700 1- Matsuno Yoshihiro Department of Surgical Pathology, Hokkaido University Hospital, Sapporo, Hokkaido, Japan aut NATIONALLICENCE 700 1- Chuman Hirokazu Department of Orthopedic Surgery, National Cancer Center Hospital, Tokyo, Japan aut NATIONALLICENCE 700 1- Yamazaki Naoya Department of Dermatology, National Cancer Center Hospital, Tokyo, Japan aut NATIONALLICENCE 700 1- Fujiwara Yasuhiro Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan aut NATIONALLICENCE 700 1- Hasegawa Tadashi Department of Surgical Pathology, Sapporo Medical University School of Medicine, Sapporo, Hokkaido, Japan aut NATIONALLICENCE 773 0- Annals of Surgical Oncology Springer-Verlag 18/10(2011-10-01), 2841-2850 1068-9265 18:10<2841 2011 18 10434 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer